Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 3/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24260523 | 0.86 | KMT2A (0.34) | — | |
| SCHEMBL24260489 | 0.83 | HSD17B10 (0.35) | ALOX15NPSR1 | |
| SCHEMBL24260525 | 0.80 | ADRB2 (0.40) | ELANEADRB2ADRA2ADRD2ADRA2C | |
| SCHEMBL24260209 | 0.78 | ALDH1A1 (0.43) | ELANE | |
| SCHEMBL24260324 | 0.73 | ELANE (0.38) | ELANEADRB2ADRA2ADRD2ADRA2C | |
| SCHEMBL24260321 | 0.73 | IRAK4 (0.38) | ELANEADRB2ADRA2ADRD2ADRA2C | |
| SCHEMBL5497597 | 0.68 | ALDH1A1 (0.42) | — | |
| SCHEMBL11425856 | 0.65 | ELANE (0.53) | ELANE | |
| SCHEMBL29925245 | 0.64 | PSMB5 (0.43) | ALOX15 | |
| SCHEMBL125575 | 0.64 | ALOX15 (0.41) | ELANEADRB2ADRA2ADRD2ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820727-B1 | Capsaicinoid prodrug compounds and their use in treating medical conditions | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820727-B1 | Capsaicinoid prodrug compounds and their use in treating medical conditions | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-11-21 | — | — | US | disclosed |
| US-11254659-B1 | Capsaicinoid prodrug compounds and their use in treating medical conditions | CENTREXION THERAPEUTICS CORPORATION (US) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820727-B1 | Capsaicinoid prodrug compounds and their use in treating medical conditions | TRPV1, TRPV2, TRPV3 | ELANE 2199/4885ADRB2 176/4885ADRA2A 147/4885 |
| US-11254659-B1 | Capsaicinoid prodrug compounds and their use in treating medical conditions | TRPV1, TRPA1, TRPV2 | ELANE 3143/4885ADRB2 481/4885ADRA2A 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.